Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27608487 | 0.88 | ALDH1A1 (0.46) | ALDH1A1CTRB1MAPT | |
| Trifluoroacetic Acid SCHEMBL27660490 | 0.82 | ALDH1A1 (0.59) | ALDH1A1TSHRFFAR3LCKFYN | |
| Trifluoroacetic Acid SCHEMBL10398782 | 0.82 | ALDH1A1 (0.59) | ALDH1A1TSHRFFAR3LCKFYN | |
| Trifluoroacetic Acid SCHEMBL479935 | 0.81 | FFAR3 (0.54) | ALDH1A1TSHRCA2FFAR3LCK | |
| Trifluoroacetic Acid SCHEMBL1977391 | 0.81 | FFAR3 (0.54) | ALDH1A1TSHRCA2FFAR3LCK | |
| Trifluoroacetic Acid SCHEMBL28878905 | 0.81 | LMNA (0.46) | ALDH1A1TSHRCA2FFAR3LCK | |
| Trifluoroacetic Acid SCHEMBL5242831 | 0.81 | FFAR3 (0.54) | ALDH1A1TSHRCA2FFAR3LCK | |
| Trifluoroacetic Acid SCHEMBL30619382 | 0.81 | FFAR3 (0.54) | ALDH1A1TSHRCA2FFAR3LCK | |
| Trifluoroacetic Acid SCHEMBL29465551 | 0.81 | FFAR3 (0.54) | ALDH1A1TSHRCA2FFAR3LCK | |
| Trifluoroacetic Acid SCHEMBL6598737 | 0.81 | LMNA (0.46) | ALDH1A1TSHRCA2FFAR3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | claimed |
| CN-1303365-A | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2001-07-11 | — | — | CN | claimed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | claimed |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-115515934-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-104701572-B | Sodium rechargeable battery | 松下知识产权经营株式会社 | 2019-04-26 | — | — | CN | disclosed |
| CN-108610332-A | Induce MDM2 self degradation E3 ubiquitin ligase dimer ester micromoleculars PROTACs | 绍兴文理学院 | 2018-10-02 | — | — | CN | disclosed |
| CN-108610333-A | Induce MDM2 self degradation E3 ubiquitin ligase dimer amide micromoleculars PROTACs | 绍兴文理学院 | 2018-10-02 | — | — | CN | disclosed |
| CN-106132962-B | Macrocyclic compounds having an aromatic P2' group as factor XIA inhibitors | 百时美施贵宝公司 | 2018-09-07 | — | — | CN | disclosed |
| CN-103958468-B | Piperidinylnaphthylacetic acids | 弗·哈夫曼-拉罗切有限公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106132962-A | Macrocyclic compounds having an aromatic P2' group as factor XIA inhibitors | 百时美施贵宝公司 | 2016-11-16 | — | — | CN | disclosed |
| EP-1198231-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-24 | — | — | EP | disclosed |
| CN-1337961-A | Heteroaryl amidines, methyl amidiues and guanidines as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2002-02-27 | — | — | CN | disclosed |
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | disclosed |
| CN-1303365-A | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2001-07-11 | — | — | CN | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001007036-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| CN-1190395-A | Substituted (sulfonic, sulfinic, sulfonamido or sulfonamido) N- [ aminoiminomethyl) phenylalkyl ] -azaheterocyclic amide compounds | RHONE POULENC RORER PHARMA (US) | 1998-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | G6PC1, GAA, GBA3 | ALDH1A1 1867/4885CTRB1 689/4885MAPT 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.